NCT06943365: TRACK-VF

Role of Anti-TREK-1 Autoantibodies in SCVF

ENROLLING BY INVITATION Last updated 24 April 2025

What this trial tests

trial testing Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies in Short-coupled Ventricular Fibrillation in 300 participants. Enrolling by invitation.

Timeline

1 May 2025

Primary endpoint
31 July 2027

31 December 2028

Quick facts

Lead sponsor	Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	300
Start date	1 May 2025
Primary completion	31 July 2027
Estimated completion	31 December 2028
Sites	1 location across Canada

Drugs / interventions tested

• Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies
• DPP6 risk haplotype

Conditions studied

• Short-coupled Ventricular Fibrillation — all drugs for Short-coupled Ventricular Fibrillation →
• Idiopathic Ventricular Fibrillation — all drugs for Idiopathic Ventricular Fibrillation →

Sponsor

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Who can join

18 and older, any sex, with Short-coupled Ventricular Fibrillation or Idiopathic Ventricular Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Short-coupled ventricular fibrillation (SCVF) is a lethal, primary electrical disorder and an important cause of unexplained cardiac arrest.1 Recent work from our group suggests that a substantial proportion of SCVF cases is associated to circulating autoantibodies targeting TREK-1, a cardiac potassium channel, resulting in an abnormal gain-of-function which is the prerequisite for the SCVF phenotype.2 This proposal is a translational multicenter study to validate anti-TREK-1 autoantibodies as a diagnostic and prognostic biomarker in a large, diversified cohort of SCVF patients (Figure 1). Functional, cellular experiments in patient-derived hiPSC cardiomyocytes and Purkinje cells will be performed to explore the cell type-specific role of TREK-1 in arrhythmogenesis, while single-nuclear RNA sequencing (snRNA-seq) will allow us to establish the transcriptomic profile (Figure 1). These results will identify the cellular substrate for SCVF.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.